Fig. 3: Sensitivities of cells containing two or three oncogenic kinases to selpercatinib, larotrectinib, entrectinib, and combination treatments. | npj Precision Oncology

Fig. 3: Sensitivities of cells containing two or three oncogenic kinases to selpercatinib, larotrectinib, entrectinib, and combination treatments.

From: Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer

Fig. 3: Sensitivities of cells containing two or three oncogenic kinases to selpercatinib, larotrectinib, entrectinib, and combination treatments.The alternative text for this image may have been generated using AI.

BaF3/RET(D898_E901del)/ETV6::NTRK3 cells (a, b), or BaF3/RET(D898_E901del)/ETV6::NTRK3/EML4::ALK cells (c, d) were cultured in 96-well plates and treated with indicated drugs for three days, and viable cells were measured using CellTiter-Glo reagent. Response curves were shown (a, c). b, d, e. Cells were treated with indicated drugs (100 nM, or as indicated) for 4 h (kinase inhibition analyses) or 24 h (apoptosis analyses). Cell lysates were analyzed by immunoblotting with indicated antibodies.

Back to article page